Tipifarnib: all 83 studies that test it
Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.
- Tipifarnib and Naxitamab for Relapsed/Refractory NeuroblastomaRecruitingNCT06540963Phase 2
- Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment TrialActive, not recruitingNCT04284774Phase 2Results posted
- Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to TherapyCompletedNCT03719690Phase 2Results posted
- Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionSTerminatedNCT03496766Phase 2Results posted
- Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)Active, not recruitingNCT03155620Phase 2Results posted
- Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid LeukemiaCompletedNCT02807272Phase 2Results posted
- Tipifarnib in Subjects With Myelodysplastic SyndromesTerminatedNCT02779777Phase 2Results posted
- Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard TherapyCompletedNCT02464228Phase 2Results posted
- Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS MutationsCompletedNCT02383927Phase 2Results posted
- Tipifarnib in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT01361464Phase 2Results posted
- Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid LeukemiaCompletedNCT00602771Phase 2Results posted
- Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast CancerCompletedNCT00470301Phase 1/2Results posted
- Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or GliosarcomaCompletedNCT00335764Phase 1/2Results posted
- Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By SurgeryCompletedNCT00281957Phase 2Results posted
- Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid LeukemiaCompletedNCT00096122Phase 1/2Results posted
- Tipifarnib in Treating Patients With Acute Myeloid Leukemia in RemissionCompletedNCT00093470Phase 3Results posted
- Tipifarnib in Treating Patients With Relapsed or Refractory LymphomaCompletedNCT00082888Phase 2Results posted
- Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast CancerCompletedNCT00082810Phase 2Results posted
- Tipifarnib and Radiation Therapy in Treating Young Patients With Brainstem GliomaCompletedNCT00079339Phase 1/2Results posted
- Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma MultiformeCompletedNCT00050986Phase 1/2Results posted
- R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform NeurofibromasCompletedNCT00021541Phase 2Results posted
- Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung CancerWithdrawnNCT05693090Phase 1
- Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)CompletedNCT04997902Phase 1/2
- Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid MalignanciesTerminatedNCT04865159Phase 1
- Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial CarcinomaStatus unknownNCT02535650Phase 2
- Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT02227901Phase 1
- Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative DisordersCompletedNCT02210858Phase 1/2
- Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple MyelomaCompletedNCT00972712Phase 1
- Efficacy and Safety of the Farnesyl-transferase Inhibitor (Tipifarnib) in Mantle Cell LymphomaTerminatedNCT00847223Phase 2
- Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Acute Myeloid LeukemiaStatus unknownNCT00510939Phase 2
- Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromesCompletedNCT00454480Phase 2/3
- Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast PhaseCompletedNCT00383474Phase 1
- A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple MyelomaTerminatedNCT00361088Phase 1/2
- Tipifarnib in Treating Patients With Anemia or Neutropenia and Large Granular Lymphocyte LeukemiaTerminatedNCT00360776Phase 2
- A Phase 2 Study of Farnesyl Transferase Inhibitor (R115777, Tipifarnib) in Patients With Refractory or Relapsed Acute Myeloid Leukemia.CompletedNCT00354146Phase 2
- Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced CancerCompletedNCT00244972Phase 1
- Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple MyelomaTerminatedNCT00243035Phase 1/2
- Study Assessing Efficacy of ZARNESTRA™ Combined With Tamoxifen in Patients With Advanced or Metastatic Breast CancerTerminatedNCT00210028Phase 2
- Phase II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma MultiformeCompletedNCT00209989Phase 2
- Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaTerminatedNCT00124644Phase 1
- Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT00112853Phase 1
- Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT00101296Phase 1
- Tipifarnib, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT00101153Phase 1
- Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast CancerCompletedNCT00100750Phase 1/2
- Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)CompletedNCT00093990Phase 3
- S0432 Tipifarnib in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT00093418Phase 2
- Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid TumorsCompletedNCT00085553Phase 1
- Tipifarnib and Radiation Therapy in Treating Patients With Unresectable Locally Advanced Pancreatic CancerCompletedNCT00077519Phase 1
- Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast CancerCompletedNCT00077363Phase 2
- Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem GliomaCompletedNCT00070525Phase 2
- Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast CancerCompletedNCT00070252Phase 1/2
- Tipifarnib in Treating Patients With Metastatic Malignant MelanomaCompletedNCT00060125Phase 2
- Tipifarnib and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00058097Phase 2
- Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerCompletedNCT00055757Phase 2
- Tipifarnib Plus Trastuzumab in Treating Patients With Metastatic Breast CancerWithdrawnNCT00054470Phase 2
- Tipifarnib Plus Tamoxifen in Treating Women With Metastatic Breast CancerCompletedNCT00052728Phase 2
- Study of Tipifarnib in Patients With High-Risk Myelodysplastic Syndrome (MDS)CompletedNCT00050154Phase 2
- Study of Letrozole Plus Tipifarnib or Placebo in the Treatment of Advanced Breast CancerCompletedNCT00050141Phase 2
- Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or GliosarcomaCompletedNCT00049387Phase 1
- Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast CancerCompletedNCT00049114Phase 2
- Study of Tipifarnib as Postconsolidation Therapy for Acute Myeloid Leukemia in Patients 60 Years and OlderCompletedNCT00048503Phase 2
- Tipifarnib in Treating Patients With Recurrent Bladder CancerCompletedNCT00047216Phase 2
- Tipifarnib in Treating Patients With Myelofibrosis and Myeloid MetaplasiaCompletedNCT00047190Phase 2
- A Phase II Study Of The Farnesyltransferase Inhibitor ZANESTRA (R115777, NSC #702818, IND #58,359) In Complete Remission Following Induction And/Or Consolidation Chemotherapy In Adults With Poor-Risk Acute Myelogenous Leukemia (AML) And High-Risk Myelodysplasia (MDS)CompletedNCT00045396Phase 2
- Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00040105Phase 1
- Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaCompletedNCT00027872Phase 2
- Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic CancerCompletedNCT00026104Phase 2
- Tipifarnib Plus Radiation Therapy After Combination Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung CancerCompletedNCT00025480Phase 1
- R115777 in Treating Patients With Advanced Solid TumorsCompletedNCT00025454Phase 1
- Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic LeukemiaCompletedNCT00025038Phase 2
- Tipifarnib in Treating Young Patients With Refractory LeukemiaCompletedNCT00022451Phase 1
- Phase II Evaluation of FTase Inhibitor (FTI)in Treatment of Advanced Multiple MyelomaCompletedNCT00012350Phase 2
- Study of the Farnesyl Transferase Inhibitor, R115777, in Combination With Topotecan (NYU 99-32)Status unknownNCT00006199Phase 1
- R115777 in Treating Patients With Recurrent or Metastatic Non-small Cell Lung CancerCompletedNCT00005989Phase 2
- Tipifarnib in Treating Patients With Advanced Hematologic CancerCompletedNCT00005967Phase 1
- Tipifarnib in Treating Patients With Recurrent or Progressive Malignant GliomaCompletedNCT00005859Phase 1/2
- Tipifarnib in Treating Patients With Myelodysplastic SyndromesCompletedNCT00005845Phase 1
- R115777 in Treating Patients Who Have Metastatic Pancreatic CancerCompletedNCT00005843Phase 2
- S9923 R115777 in Treating Patients With Advanced Colorectal CancerCompletedNCT00005833Phase 2
- S9924 R115777 in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerCompletedNCT00005832Phase 2
- Gemcitabine With or Without Tipifarnib (R115777) in Treating Patients With Advanced Pancreatic CancerCompletedNCT00005648Phase 3
- R115777 in Treating Patients With Relapsed Small Cell Lung CancerCompletedNCT00005041Phase 2
- R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous LeukemiaCompletedNCT00004009Phase 1